Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-03-21
Tempus AI, Inc.
Tempus sells molecular diagnostics, clinical workflow software, and de-identified data and analytics tools to providers and life sciences customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A regulated data moat with margin work left
The upside case rests on converting test volume and workflow embed into a trusted data-rights and applications business with better economics. The opportunity is meaningful, but the stock needs cleaner proof of revenue conversion and sustained EBITDA to earn a much higher valuation.

Analysis

Thesis
Tempus can compound from a fast-growing diagnostics company into a trusted precision-medicine operating layer by turning test volume, workflow embed, and governed data rights into higher-margin applications and biopharma revenue; the upside is real, but the multiple only expands if EBITDA and trust both hold.
Last Economy Alignment
Tempus benefits as cheaper AI makes its proprietary data, regulated assays, and embedded workflow more valuable. Low seat exposure and real switching friction help, but reimbursement, privacy, and trust keep it below true infrastructure status.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
The upside case is not that Tempus becomes a pure software company; it is that it becomes a better business than a normal lab. If diagnostics keeps feeding proprietary data, and that data keeps lifting workflow and life-science products, revenue mix should improve enough to support a premium to most diagnostics peers. I do not underwrite a hyperscale software multiple because reimbursement, regulated updates, and trust reviews still slow monetization.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not lack of demand; it is failure to turn demand into durable, recognized, high-quality revenue while preserving trust. Tempus must keep diagnostics growth strong, convert contracted data demand into revenue, integrate acquired assets cleanly, and prove EBITDA durability. A reimbursement shock, privacy or PHI incident, or a stall in mix shift would likely compress the valuation back toward diagnostics peers.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.62
They control a hard-to-copy mix of clinical data rights, approved tests, and doctor workflow hooks, so cheaper AI makes their dataset more useful instead of replacing it. The risk is that reimbursement, privacy rules, or a trust failure interrupt the flywheel before the software layer earns true platform economics.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$77.93
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case